CTLA-4 engagement has been reported to block extracellular signal-regulated kinase and Jun NH2-terminal kinase activity 29 and the induction of IL-2 transcription. [30] [31] [32] TCR/CD3 ligation induces antigen-induced cell death (AICD) as mediated by Fas (CD95/APO-1) and Fas ligand (CD95L) interactions and the activation of caspases, a process that ensures the elimination of self-reactive thymocytes and peripheral blood lymphocytes. [33] [34] [35] [36] Although AICD operates in CTLA-4 Ϫ/Ϫ T cells, 14 little is known regarding whether CTLA-4 has the capacity to block TCR-mediated signals leading to AICD. In this regard, T-cell hybridomas have served as a model for the study of AICD 33, 34 ; in particular, the hybridoma DC27.10 has been previously studied for the role of costimulation in the induction of apoptosis. 37 In this report, we demonstrate that CTLA-4 can block AICD in transfectants of the murine hybridoma DC27.10 via inhibition of Fas ligand (FasL) surface expression. These findings support a model in which CTLA-4 interferes with an early TCR-signaling event linked to both IL-2 production and FasL expression.
Study design Cells, reagents, and antibodies
Murine T-cell hybridoma DC27.10 (gift from Dr R. Zamoyska, Medical Research Council, London, United Kingdom) was cultured in RPMI-1640 containing fetal bovine serum 5% (vol/vol) (Sigma, St Louis, MO), L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 g/mL) (Life Technologies, Grand Island, NY) at 37°C, and 5% CO 2 . DC27.10 transfectants carrying different transfected forms of human CTLA-4 (wild-type human CTLA-4, Y201-2F) were generated as described. 38 Hamster anti-murine CD3 (145-2C11) was purchased from American Type Culture Collection (Manassas, VA), mouse anti-human CTLA-4 (BNI3.1) was purchased from Immunotech (Marseilles, France). Mouse immunoglobulin G2a (specific for 2,4,6-trinitrophenol [TNP]), hamster anti-mouse CD28 (37.10) purified rat anti-mouse IL-2 (JES6-1A12), biotinylated rat anti-mouse IL-2 (JES6-5H4), and biotinylated anti-FasL were purchased from Pharmingen (San Diego, CA). Avidinperoxidase was purchased from Sigma. ABTS tablets and recombinant mouse IL-2 were purchased from Boehringer Mannheim (Indianapolis, IN). Mouse anti-hamster was purchased from Sigma. Phycoerythrinlabeled streptavidin was a gift from the laboratory of Dr Lee Nadler, Dana-Farber Cancer Institute (Boston, MA).
Stimulation assay
For all experiments, stimulation of T-cell hybridoma was performed by means of antibodies bound to plates. The antibodies were added at their designated concentration in a 96-well microtiter plate and left to adsorb overnight at 4°C. The wells were washed twice with complete media, followed by the addition of cells at a density of 1.5 ϫ 10 5 cells per well and incubation for 24 hours at 37°C. The cells were then harvested and analyzed for apoptosis. The supernatant was frozen for later measurements of IL-2 by enzyme-linked immunosorbent assay (ELISA) (Pharmingen).
Apoptosis measurements
The samples were fixed with propidium iodide (PI) staining buffer (sodium citrate 0.1%, sodium dodecyl sulfate 1%, 50 g/mL PI) overnight at 4°C. Apoptosis was analyzed on an Epics XL flow cytometry system (Coulter, Hialeah, FL) by gating on the subdiploid population below the G1 peak.
Results and discussion
Stable transfectants of the T-cell hybridoma DC27.10 were initially generated that express either wild-type human CTLA-4 (CTLA-4 WT), or a mutant form with a substituted cytoplasmic tyrosine at position 201 in the YVKM motif (Y201-F). 27 Both CTLA-4 WT and Y201-F express the coreceptor at moderate levels with stable expression of TCR/CD3 and CD28 ( Figure 1A ). To assess whether CTLA-4 could influence the ability of the TCR/ CD3 to induce apoptosis, anti-CD3 was immobilized on plates at a concentration of 0.5 g/mL in the presence or absence of anti-CTLA-4 at a concentration of 10 g/mL. Cell death was assessed 24 hours after stimulation by examining the DNA content by PI CTLA-4 inhibits AICD in CTLA-4 transfectants. Cells were stimulated on a 96-well plate coated with anti-CD3 (145-2C11) at a concentration of 0.5 g/mL and with anti-CTLA-4 (10 g/mL). Anti-TNP control antibody was added to keep a final concentration of 10.5 g/mL with anti-CD3 alone. AICD was determined by PI as described in "Study design." Ⅺ indicates media; f, ␣CD3; and p, ␣CD3 ϩ ␣CTLA-4. (C) CTLA-4 inhibits AICD in a concentration-dependent manner. Anti-CD3 was used at a concentration of 0.5 g/mL, while anti-CTLA-4 was used at concentrations of 2, 5, and 10 g/mL. Anti-TNP control antibody was added to keep the final concentrations equivalent. f indicates vector; p, CTLA-4 WT; and Ⅺ, Y201F. (D) CTLA-4 inhibits AICD induced by anti-CD3 in conjunction with anti-CD28. Anti-CD3 was used at 0.5 g/mL; anti-CD28 at 5 g/mL; and anti-CTLA-4 at 5 g/mL. Anti-TNP control antibody was added to keep the final concentrations equivalent. Ⅺ indicates media; f, ␣CD3; o, ␣CD3 ϩ ␣CD28; p, ␣CD3 ϩ ␣CD28 ϩ ␣CTLA-4. For personal use only. on July 9, 2017. by guest www.bloodjournal.org From staining as described in "Study design." The results were confirmed by DNA laddering techniques (data not shown). Anti-CD3 induced AICD in transfected cells in the range of 50% to 65% as observed in 7 experiments (data not shown). 33, 34 Results were expressed as values relative to the anti-CD3 control. Coligation with anti-CTLA-4 caused a 60% reduction in the percentage of cells undergoing apoptosis in cells transfected with CTLA-4 WT ( Figure  1B) . In 7 experiments, anti-CTLA-4 blocked AICD within a range of 60% to 80%. No effect of anti-CTLA-4 was evident in vectortransfected control cells ( Figure 1B) . The efficacy of the AICD blocking was proportional to the concentration of anti-CTLA-4 in the range of 2 to 10 g/mL ( Figure 1C ). Inhibition by CTLA-4 was also observed when anti-CD28 was coligated with anti-CD3 ( Figure 1D ). These findings indicate that coligation of CTLA-4 can attenuate anti-CD3-induced AICD.
The cytoplasmic tail of CTLA-4 has a tyrosine-based motif YVKM that binds several intracellular signaling proteins. [19] [20] [21] [22] Mutation of the tyrosine within the YVKM sequence renders the motif unable to bind to these proteins. Disruption of the YVKM motif rendered CTLA-4 significantly less effective in blocking AICD (Figure 1B-C) . A titration of anti-CTLA-4 showed that this partial blockage in Y201-F was observed only at the highest concentration of anti-CTLA-4 ( Figure 1C ). This partial inhibition was also observed with anti-CD3 ϫ CD28 cross-linking ( Figure 1D ). These observations indicate that the optimal blockage of AICD by CTLA-4 is dependent on an intact YVKM motif.
CTLA-4 inhibition of IL-2 production is a hallmark of the blockage effects on T-cell activation. 6, 7 Indeed, IL-2 production was inhibited by anti-CTLA-4 in a dose-dependent manner of 2 to 10 g/ml of antibody on the CTLA-4 WT cells, albeit slightly less than observed for AICD (Figure 2A ). To control for the possibility that the loss of IL-2 contributed to AICD, exogenous recombinant IL-2 was added in excess to cultures with anti-CD3 plus anti-CTLA-4 ( Figure 2B ). Under these conditions, IL-2 did not restore the induction of cell death, indicating that CTLA-4 blockage of AICD was not due to its blockage of IL-2.
AICD in T-cell hybridomas is mediated by the expression of Fas (CD95/APO-1), the expression of FasL (CD95L), and the activation of caspases. 33, 34 To investigate whether CTLA-4 blocks AICD by means of an inhibitory effect on FasL expression, cells were incubated with anti-CD3 in the presence or absence of anti-CTLA-4 followed by staining for FasL surface expression. Under these conditions, anti-CTLA-4 coligation caused a 4-to 5-fold reduction in the level of FasL expression ( Figure 3A ). This level of inhibition correlated well with the overall reduction of AICD ( Figure 1A-D) . Fas expression was also reduced, but to a lesser extent and less reproducibly (data not shown). The blockage of FasL expression was observed reproducibly in 4 experiments. To confirm that the AICD in our hybridomas was mediated by Fas/FasL binding, blocking anti-FasL antibodies were added to cultures and found to completely inhibit cell death ( Figure 3B ). CTLA-4 therefore impinges on TCR-induced apoptosis by blocking the expression of FasL.
Our findings provide the first evidence that CTLA-4 has the capacity to block TCR-signaling events that lead to FasL expression and AICD. Scheipers and Reiser 44 , however, have reported a role of CTLA-4 in the promotion of AICD. In their study, concanavalin A (ConA) is used as a stimulating agent instead of direct TCR cross-linking. It may be that stimulating with ConA and anti-CTLA-4 antibodies delivers different signals than using antibodies to directly cross-link the TCR with CTLA-4. Our study was not intended to address the physiological relevance of CTLA-4 on antigen-induced cell death, but rather to serve as a model to examine the point of blockage by CTLA-4 in the signaling cascade. With this perspective, our findings suggest that the coreceptor can block TCR signaling prior to the bifurcation of signals leading to FasL and IL-2 production ( Figure 3C ). Further CTLA-4 can block TCR signaling events that result in both positive (eg, IL-2 production) and negative outcomes (ie, apoptosis). Although the nature of signals that distinguish these events is unknown, p56 lck and NF-AT have been reported to regulate both FasL and IL-2 expression. 39 Other transcription factors, c-Myc, Egr 2, and Egr 3, have been implicated in FasL expression. [40] [41] [42] In our system, the inhibitory effect of FasL expression and AICD must be an active process since it depends on the integrity of the cytoplasmic tail of the receptor (ie, YVKM motif). This contrasts with previous studies that demonstrated anti-CTLA-4 rescue of thymocytes from cell death by blockage of negative signaling. 43 In this context, our cellular assay could be used as an assay to distinguish between antibodies that operate by actively generating negative signals vs those that simply block engagement of the receptor with CD80/CD86. Further analysis will also be needed to define which of these associated proteins regulates the blockage of AICD and IL-2 production. /mL) , anti-TNP (10 g/mL) control, and anti-CD3 (0.5 g/mL). The cells were harvested after 6 hours, stained with biotinylated anti-FasL antibody followed by fluorescein isothiocyanate-labeled avidin. Subsequently, the cells were gated and analyzed by flow cytometry. A histogram of FasL staining on FL-1 is displayed. (B) Anti-FasL blocks anti-CD3-induced apoptosis in DC27.10 transfectants. CTLA-4 WT transfectants were stimulated with the indicated antibodies bound to plates: anti-CTLA-4 (10 g/mL), anti-TNP (10 g/mL) control, and anti-CD3 (0.5 g/mL) with or without soluble blocking anti-FasL antibody (10 g/mL). The cells were harvested 24 hours later and stained with PI. Apoptosis was measured as described in "Study design." Ⅺ indicates control; o, ␣CD3; f, ␣CD3 ϩ ␣FasL. (C) Model of CTLA-4 blockage of IL-2 production and AICD. The coreceptor acts to dampen TCR/CD3 signaling at an early stage in T-cell activation prior to the bifurcation of signals leading to IL-2 production and FasL expression and AICD.
